Printer Friendly

Concomitant infection with Leishmania donovani and L. major in single ulcers of cutaneous leishmaniasis patients from Sudan.

1. Introduction

Leishmaniasis is a vector-borne parasitic disease caused by intramacrophage protozoa of the genus Leishmania, transmitted generally by at least 30 species of sand flies (either Phlebotomus or Lutzomyia genera) and rarely by congenital and parenteral routes [1, 2]. Depending on the species of Leishmania involved, humans and a wide range of mammals can act as reservoirs [3]. At least four major clinical forms of leishmaniasis are recognised: cutaneous leishmaniasis (CL), either diffused or localized, mucocutaneous leishmaniasis (ML), visceral leishmaniasis (VL), fatal if untreated, and the post-kala-azar dermal leishmaniasis (PKDL).

The disease is endemic in the tropical and subtropical regions of 88 countries [4, 5]. Population displacements and increasing cases of Leishmania/HIV coinfection brought new dramatic concerns to the disease especially in developing countries [6]. Leishmaniasis-affected individuals are estimated to be about 12-13 million worldwide with an annual incidence of 1-1.5 million new cases of CL and 500,000 of VL [4, 7]. However, the real burden of leishmaniasis is greatly underestimated and a substantial number of cases remain unrecorded and misdiagnosed [8, 9]. In Sudan leishmaniasis represents a serious health problem and outbreaks occur periodically causing a high number of victims [10-12]. Many different clinical forms of Leishmaniasis coexist. CL is caused by L. major and transmitted by Phlebotomus papatasi. It is endemic in the central and northern part of the country [13], However, recently, CL due to L. donovani has been well documented [14]. VL is the most serious form caused by L. donovani, transmitted by Phlebotomus orientalis [15, 16], and endemic in the eastern part of the country [17, 18]. However, scattered cases have been reported from areas not known to be endemic in the southern, northern, and western parts of the country [11]. Both anthroponotic transmission and zoonotic transmission of VL were thought to occur [15, 19-21]. PKDL occurs in high rates during or shortly after treatment. At least 50% of VL patients develop PKDL and this percentage is higher than in any other VL endemic area [22-24]. PKDL patients are thought to act as human reservoir for the parasite [25]. Sudanese mucosal leishmaniasis (SML) is a rare and particular form of ML. Unlike ML, SML starts usually as primary mucosal disease, without being preceded or accompanied by cutaneous lesions. SML occurs in areas endemic for VL [26, 27]. Leishmania/HlV coinfection is a growing concern particularly in the East [6].

Few studies have been reported on the naturally mixed infection with different species or strains of Leishmania in immunocompetent patients. However, natural infection with more than one Leishmania, especially where foci of two species overlap, is more prevalent than previously reported. Nonetheless, the degree of laboratory detection of such phenomenon remains unclear [28].

The general aim of this study was to genetically characterize Leishmania isolates from patients with various clinical manifestations. Here we report for the first time the detection of three cases of mixed L. donovani and L. major infections in three out of five patients diagnosed as cutaneous Leishmaniasis patients with no apparent clinical symptoms of VL.

2. Materials and Methods

2.1. Clinical Samples. One hundred and eight samples composed of blood (HB), bone marrow (HBM), lymph node aspirates (HLN), extracted DNA and cultured parasites were obtained from 69 patients clinically suspected of leishmaniasis. From 21 of these patients, HBM, HB, and HLN aspirates were taken. Seven HB samples and one HLN were collected from eight symptomatic VL patients at Medecins Sans Frontieres-Suisse (MSF-CH) Leishmaniasis clinic inside the local Tabarak Allah hospital (Gedarif, Sudan). Other 20 HB and 5 HMB were collected from south Gedarif (Table 1). All described samples were collected from known VL endemic areas. Clinical samples were spotted on Whatman filter paper grade 3; each filter paper sample was stored in a separate polyethylene bag at room temperature till further analysis.

Five samples were taken from five patients presented at the Institute of Endemic Disease, University of Khartoum, Sudan (IEND), with typical CL ulcers. In addition, ten extracted genomic DNA of seven VL, one CL, one ML, and one PKDL samples were kindlyprovided by the same institute (Table 1). CL patients were not from VL known endemic areas anddid notshowclinicalsymptomsofVL. Asinglecutaneous aspirate from the edges of the ulcer was inoculated into bottles containing biphasic media (NNN) and incubated at 24[degrees]C. Cultures were examined microscopically for parasite growth and the successfully cultured isolates were mass-cultured in 200 mL of RPMI-1640 supplemented with 10% foetal calf serum (FCS) and 1% of Penicillin/Streptomycin solution. L. major MON 25, kindly provided by the Leishmania reference centre, Italy, was included in this study.

3. Biomolecular Assay

3.1. DNA Extraction. DNA of the cultured parasites was extracted using phenol/chloroform method as described elsewhere [29].

Filter papers with spotted biological material (lymph node or bone marrow aspirates or blood) were punched out with a paper puncher. To prevent DNA contamination among samples, clean sheet of paper was sprayed with DNA decontaminant [30] using MicroSol 3+ solution and was punched several times as recommended by the World Health Organization (available at http://www.who .int/hiv/topics/drugresistance/dbs_protocol.pdf) for HIV patients. DNA extraction was performed using QIAamp DNA Mini Kit according to the manufacturer's instructions.

3.2. Real-Time PCR Assay. As an initial screening, a real-time PCR was conducted to investigate the presence of Leishmania complexes (L. viannia, L. mexicana, L. donovani/infantum, and L. major) in all samples. The primers Lid-f and Lidr which generate a 80 bp fragment of the GPI gene [31] were used with the probe TaqMan MGB Lid-probe 5ATCGGCAGGTTCT-3 labeled with the fluorescent reporter dye FAM (6-carboxyfluorescein) at the 57end and with the fluorescent quencher dye TAMRA (tetra-methyl carboxyrhodamine). Real-time PCR was performed in a final volume of 20 [micro]L containing 3 [micro]L of DNA, 10 [micro]L of FastStart TaqMan Probe Master (Rox)1X (Roche Mannheim, Germany), 0.4 [micro]M of both primers, and 0.3 [micro]M of the probe. The thermal cycling profile consisted of an initial activation at 95[degrees]C for 10 min, followed by 45 cycles each consisting of denaturation at 95[degrees] C for 15 sec and annealing/extension at 60[degrees]Cfor 30 sec. Negative (sterile water) and positive (DNA extracted from L. infantum MON-1, MHOM/Tn/80/IPT1, IZSVe. Italy) controls were included in each run of real-time PCR reaction. Real-time PCR was carried out on a 7900HT fast real-time PCR system (Applied Biosystems).

To determine the genetic profile of Leishmania spp., DNA from each positive sample was subjected to the amplification of the cytochrome oxidase II gene.

3.3. Cytochrome Oxidase II PCR. PCR was performed as described previously for the targeted cytochrome oxidase II for all leishmaniasis positive samples [32].

The reaction was performed in a final volume of 50 [micro]L containing 5 [micro]L of DNA, 5 [micro]L of PCR buffer 1X (Applied Biosystems, Foster City, CA), 2 mM of MgCl2 (Applied Biosystems, Foster City, CA), 0.4 [micro]M of each primer, 0.2 mM of dNTPs (Applied Biosystems, Foster City, CA), and 2U of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA). Amplifications were carried out in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA) with the following thermal cycling profile: denaturation for 10 min at 95[degrees]C, followed by 35 cycles each consisting of 30 sec at 94[degrees]C, 30 sec at 50[degrees]C, 45 sec at 72[degrees] C, and a final extension step for 7 min at 72[degrees] C. Negative and positive controls were included in each run of PCR as described above.

All the PCR products were analysed on 7% acrylamide gel, visualized by silver staining, and subsequently subjected to sequencing. PCR products were sequenced using the Big Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). The products of the sequencing reactions were purified using PERFORMA DTR Ultra 96-Well kit (Edge BioSystems, Gaithersburg, MD, USA) and sequenced in a 16-capillary ABI PRISM 3130xl Genetic Analyser (Applied Biosystem, Foster City, CA, USA). Sequence data were assembled and edited with SeqScape software v2.5 (Applied Biosystems, Foster City, CA, USA). Sequences obtained were aligned and studied. The sequences which showed overlapping nucleotides peaks were subjected to cloning.

3.4. Internal Transcribed Spacer (ITS) PCR. ITS PCR was performed in the three cutaneous samples that showed overlapping nucleotides peaks in the COII sequences. The ITS region (1044 pb nucleotides) was amplified with the Leishmania specific primers: LITSR [33] and a new designed primer ITSRR (5'-AGAGTGAGGGCGCGGATA-3') that amplify L. donovani complex and L. major.

The reaction was performed in a final volume of 50 [micro]L containing 0.5 [micro]L of DnA, 5 [micro]L of PCR buffer 1X (Applied Biosystems, Foster City, CA), 2mM of MgCl2 (Applied Biosystems, Foster City, CA), 0.4 [micro]M of each primer, 0.2 mM of dNTPs (Applied Biosystems, Foster City, CA), and 2.5 U of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA). Amplifications were carried out in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA) with the following thermal cycling profile: denaturation for 10 min at 95[degrees]C, followed by 35 cycles each consisting of 30 sec at 94[degrees]C, 30 sec at 50[degrees]C, 1 minute at 72[degrees]C, and a final extension step for 10 min at 72[degrees]C. Negative and positive controls were included in each run of PCR as described above.

All the PCR products were analyzed on 7% acrylamide gel and visualized as described above and cloned.

3.5. Cloning Assay. The three PCR products of the COII and the three PCR products of the ITS genes were cloned separately into the PCR-II vector using a dual-promoter TOPO TA cloning kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Plasmids with the desired inserts were isolated from positive Escherichia coli colonies by using a GenElute plasmid miniprep kit (Sigma-Aldrich, St. Louis, MO). DNA extracts from at least 30 randomly selected colonies were sequenced as described above.

3.6. Phylogenetic Analysis. Sequencing data were assembled and edited with SeqScape software v2.5 (Applied Biosystems) and analyzed. Phylogenetic analysis was conducted by using the neighbor-joining method with 1000 bootstrap replicates implemented in MEGA 5 software [34].

4. Results

Overall, the diagnosis of leishmaniasis was confirmed by realtime PCR in 40 patients out of 69 (58%). The real-time PCR confirmed 58 samples out of 110 (53%) as Leishmania positive. The positivity in real-time PCR was higher for HLN samples (66%) compared to HBM (57%) and HB (29%).

4.1. Cytochrome Oxidase II Sequence Analysis and Phylogeny

4.1.1. Direct Sequence Analysis. Samples associated with VL, PKDL, and ML clinical forms showed a unique sequence pattern with 100% genetic homology to L. donovani AY660023.1 reference sequences deposited in GenBank (Figure 1). One sequence associated with VL clinical symptoms (14 HBM) showed the highest identity (98.9%) to L. infantum MHOM/TN/80/IPT1 reference sequence and a similarity of 98.1% to the abovementioned L. donovani GenBank reference sequence (Figure 1). The genetic homology between L. donovani GenBank reference sequence and L. infantum sequence used in this study was 98.7%.

Two sequences associated with CL samples clustered within the L. donovani group (numbers 107 and 111) with 100% genetic identity (Figure 1).

The remaining three CL sequences showed overlapping nucleotides peaks (Figure 2) and therefore were cloned.

4.1.2. Cloning Sequences Analysis. Thirty-four, twenty-nine, and thirty-six sequences were obtained from cloning of CL samples numbers 108,109, and 110, respectively.

Phylogenetic analysis of the abovementioned colonies (Figure 3) revealed two different sequence patterns, corresponding to L. donovani with genetic similarity range between 99.5% and 100% to L. donovani AY660023 GenBank reference sequence and to L. major with genetic similarity ranging between 98.9 and 99.3% to L. major EF633106 GenBank reference sequence. The genetic similarity between the two GenBank reference sequences used here was 89.4%.

4.1.3. ITS Sequence Analysis and Phylogeny. Twenty-three, fourteen, and eighteen sequences were obtained from cloning of samples numbers 108, 109, and 110, respectively. As for COII, the phylogenetic analysis of the ITS cloning sequences revealed two different sequence patterns, corresponding to L. donovani with 99.5-100% genetic similarity to L. donovani AJ634357 GenBank reference sequence and 99.8-100% to L. major FJ753391 GenBank reference sequence. The genetic similarity between L. major and L. donovani used in this study was 93.5% (Figure 4).

All the representative sequences showed in the trees (Figures 1, 3, and 4) have been submitted to GenBank (accession numbers from KF815198 to KF815226).

5. Discussion

The COII and the ITS genes gave concordant results and confirmed naturally mixed infection with L. major and L. donovani from a single cutaneous aspirate in the three CL patients who presented no evident VL clinical signs.

L. major and L. donovani have different transmission vectors and distinct biologic properties and epidemiologic features and both have been reported as etiologic agents of CL in Sudan.

CL due to L. major LON1 is transmitted by P. papatasi in arid and semi-arid areas and circulates among rodents [35], while the vector that transmits CL due to L. donovani has not been established yet.

Coinfection with different Leishmania has been reported in closely related Leishmania species such as L. braziliensis, L. panamensis [36], L. major, and L. arabica [37]. The only two reports on concomitant natural infection with L. donovani and L. major were reported in Iraq where the two species were isolated from two different sites, the bone marrow and cutaneous lesions from kala-azar suffering patients [38] and in Kenya where isolation was achieved in a spleen aspirate culture from a clinically relapsed kala-azar suffering patient [39]. Concomitant infection with divergent Leishmania species has also been reported. The two species L. infantum and L. major have been isolated from the spleen of VL/HIV immune-compromised patient [40]; L. chagasi and L. amazonensis have been isolated from a diffuse cutaneous leishmaniasis case in Bolivia [41].

In our study, the three coinfected patients were presented with typical localized cutaneous ulcers, with neither evident signs of systemic illness nor immunosuppression or VL. All three patients originated from a VL non endemic area and had no history of travelling to a known VL endemic area. However, even if visceral involvement or immunosuppression was not clinically suspected, no other clinical or laboratory examinations were carried out.

The occurrence and frequency of natural infection with more than one Leishmania, especially where foci of two species overlap, are believed to be more prevalent than reported. It has been demonstrated that in co-cultivation of more than one Leishmania the dominant species tend to inhibit the growth of the other; consequently the degree of laboratory detection of such phenomenon remains unclear and likely underestimated [28, 42].

In our case, the two species were likely maintained because the cultured parasites were harvested and extracted during early growth at the third day of culture. However, after cloning, the number of colonies related to L. major genetic group was higher compared to that related to L. donovani genetic group. This may suggest the dominance of L. major species in the co-culture; however, it is also possible that the PCR conditions were more efficient towards L. major genome.

Assumption of circulation of more than one strain/hybrid of L. major and L. donovani was demonstrated by the presence of more than one sequence pattern of L. major and L. donovani within the same patient (Figures 3 and 4). Recent studies have demonstrated the presence of genetically different populations of P papatasi in Sudan [43] that could be able to transmit different strain/hybrids. Moreover, high polymorphism has been attributed to L. major causing cutaneous diseases in Iran [44]. The hypothesis of the circulation of more than one strain/hybrid of L. donovani among Sudanese patients is supported by our findings after analyzing clones of the ITS gene and the GP63 gene from different VL patients (data not shown). However, the intraspecific variations of Leishmania species among Sudanese patients and its correlation with clinical signs need to be explored.

The other two cutaneous cases were identified to be caused by L. donovani only as reported by other the authors [14].

The transmission route of naturally mixed infection remains debated. P. papatasi is not a vector of visceral Leishmaniasis and is refractory to the infection by L. infantum and L. donovani [45,46]. However, an experimental evidence of P papatasi infection with hybrid strains of L. infantum/L. major causing visceral disease in HIV-positive patients has been documented [47]. Based on these results, P. papatasi has been suggested as vector of this hybrid in nature [47].

All the other cases of VL (except one case), ML, and PKDL were caused by L. donovani; however, the limited numbers of ML and PKDL samples did not allow investigating whether other species of Leishmania were involved.

Cytochrome oxidase II gene confirmed its good capability to discriminate among different species of Leishmania. Previously, an extensive research on VL based on the isoenzyme classification led to the conclusion that L. donovani is the only cause of visceral leishmaniasis in Sudan [48]. In our study, cytochrome oxidase II revealed one sample with sequences very similar to L. infantum genetic group and further studies are needed to confirm this finding. However, the correspondence between genetic and isoenzyme classifications is still debated and a revision of the taxonomy of the genus Leishmania has been proposed by other researchers [49, 50].

6. Conclusion

To the best of our knowledge this is the first report of L. donovani and L. major co-infection in Sudan. Additionally no other cases of such co-infection from the same cutaneous sample were reported.

This finding has important implications regarding the diagnosis, the choice of the most appropriate therapy, and the possibility of developing drug resistance.

The limited number of cutaneous samples examined does not allow predicting the frequency of this coinfection. However, the presence of L. donovani in all the five cutaneous samples suggests caution in the followup of CL patients who could later develop VL symptoms. Many aspects of leishmaniasis in Sudan still need to be explored, such as the prevalence of different species and vectors and the competence of Phlebotomus spp. in transmitting different Leishmania species.

http://dx.doi.org/10.1155/2014/170859

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors wish to thank the staff of MSF-CH Leishmaniasis Clinic, Tabarak Allah Hospital (Gedarif, Sudan) for providing some of the clinical samples; Dr. Fabrizio Vitale from the National Reference Centre for Leishmaniasis (C.Re.Na.L., Sicily) for providing the L. major positive control. This work has been partially supported by the Veneto region (Italy).

References

[1] A. J. Magill, "Epidemiology of the Leishmaniases," Dermatologic Clinics, vol. 13, no. 3, pp. 505-523, 1995.

[2] B. L. Herwaldt, "Laboratory-acquired parasitic infections from accidental exposures," Clinical Microbiology Reviews, vol. 14, no. 4, pp. 659-688, 2001.

[3] R. W. Ashford, "Leishmaniasis reservoirs and their significance in control," Clinics in Dermatology, vol. 14, no. 5, pp. 523-532, 1996.

[4] P. Desjeux, "Leishmaniasis: public health aspects and control," Clinics in Dermatology, vol. 14, no. 5, pp. 417-423, 1996.

[5] P. Desjeux, "Leishmaniasis: current situation and new perspectives," Comparative Immunology, Microbiology and Infectious Diseases, vol. 27, no. 5, pp. 305-318, 2004.

[6] J. Alvar, P. Aparicio, A. Aseffa et al., "The relationship between Leishmaniasis and AIDS: the second 10 years," Clinical Microbiology Reviews, vol. 21, no. 2, pp. 334-359, 2008.

[7] P. Desjeux, "The increase in risk factors for Leishmaniasis worldwide," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 95, no. 3, pp. 239-243, 2001.

[8] P. J. Guerin, P. Olliaro, S. Sundar et al., "Visceral Leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda," The Lancet Infectious Diseases, vol. 2, no. 8, pp. 494-501, 2002.

[9] H. W. Murray, J. D. Berman, C. R. Davies, and N. G. Saravia, "Advances in Leishmaniasis," The Lancet, vol. 366, no. 9496, pp. 1561-1577, 2005.

[10] E. E. Zijlstra and A. M. el-Hassan, "Leishmaniasis in Sudan. Visceral Leishmaniasis," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 95, supplement 1, pp. S27-S58, 2001.

[11] O. F. Osman, P. A. Kager, and L. Oskam, "Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects," Tropical Medicine & International Health, vol. 5, no. 8, pp. 553-562, 2000.

[12] E. A. G. Khalil, A. M. Musa, S. H. H. Elgawi et al., "Revival of a focus of visceral Leishmaniasis in central Sudan," Annals of Tropical Medicine and Parasitology, vol. 102, no. 1, pp. 79-80, 2008.

[13] S. H. el-Safi and W. Peters, "Studies on the Leishmaniases in the Sudan--1. Epidemic of cutaneous Leishmaniasis in Khartoum," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 85, no. 1, pp. 44-47, 1991.

[14] E. M. Elamin, I. Guizani, S. Guerbouj et al., "Identification of Leishmania donovani as a cause of cutaneous Leishmaniasis in Sudan," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 102, no. 1, pp. 54-57, 2008.

[15] A. M. el-Hassan, E. E. Zijlstra, S. E. Meredith, H. W. Ghalib, and A. Ismail, "Identification of Leishmania donovani using a polymerase chain reaction in patient and animal material obtained from an area of endemic kala-azar in the Sudan," Acta Tropica, vol. 55, no. 1-2, pp. 87-90, 1993.

[16] D. A. Elnaiem, R. D. Ward, H. K. Hassan, M. A. Miles, and I. A. Frame, "Infection rates of Leishmania donovani in Phlebotomus orientalis from a focus of visceral Leishmaniasis in eastern Sudan," Annals of Tropical Medicine and Parasitology, vol. 92, no. 2, pp. 229-232, 1998.

[17] A. M. el-Hassan, E. E. Zijlstra, A. Ismael, and H. W. Ghalib, "Recent observations on the epidemiology of kala-azar in the eastern and central states of the Sudan," Tropical and Geographical Medicine, vol. 47, no. 4, pp. 151-156, 1995.

[18] E. A. G. Khalil, E. E. Zijlstra, P. A. Kager, and A. M. el Hassan, "Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan," Tropical Medicine and International Health, vol. 7, no. 1, pp. 35-44, 2002.

[19] D. A. Elnaiem, M. M. Hassan, R. Maingon et al., "The Egyptian mongoose, Herpestes ichneumon, is a possible reservoir host of visceral Leishmaniasis in eastern Sudan," Parasitology, vol. 122, no. 5, pp. 531-536, 2001.

[20] J. Dereure, S. H. el-Safi, B. Bucheton et al., "Visceral Leishmaniasis in eastern Sudan: parasite identification in humans and dogs; host-parasite relationships," Microbes and Infection, vol. 5, no. 12, pp. 1103-1108, 2003.

[21] M. M. Hassan, F. M. A. Elrabaa, R. D. Ward, R. D. C. Maingon, and D. A. Elnaiem, "Detection of high rates of in-village transmission of Leishmania donovani in eastern Sudan," Acta Tropica, vol. 92, no. 1, pp. 77-82, 2004.

[22] WHO, "Control of the Leishmaniasis," Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis, WHO, Geneva, Switzerland, 2010.

[23] E. E. Zijlstra, A. M. Musa, E. A. G. Khalil, I. M. el Hassan, and A. M. el-Hassan, "Post-kala-azar dermal Leishmaniasis," The Lancet Infectious Diseases, vol. 3, no. 2, pp. 87-98, 2003.

[24] E. E. Zijlstra, A. M. el-Hassan, and A. Ismael, "Endemic kalaazar in eastern Sudan: post-kala-azar dermal Leishmaniasis," American Journal of Tropical Medicine and Hygiene, vol. 52, no. 4, pp. 299-305, 1995.

[25] A. M. el Hassan and E. A. G. Khalil, "Post-kala-azar dermal Leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan?" Tropical Medicine and International Health, vol. 6, no. 9, pp. 743-744, 2001.

[26] A. M. el-Hassan, S. E. Meredith, H. I. Yagi et al., "Sudanese mucosal leishmaniasis: epidemiology, clinical features, diagnosis, immune responses and treatment," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 89, no. 6, pp. 647-652, 1995.

[27] A. M. el-Hassan and E. E. Zijlstra, "Leishmaniasis in Sudan--2. Mucosal Leishmaniasis," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 95, supplement 1, pp. S19-S26, 2001.

[28] M. E. Ibrahim, A. J. Smyth, M. H. Alid, D. C. Barker, and A. Kharazmi, "The polymerase chain reaction can reveal the occurrence of naturally mixed infections with Leishmania parasites," Acta Tropica, vol. 57, no. 4, pp. 327-332, 1994.

[29] T. Maniatis, E. F. Fritsch, and K. J. Sambrook, Purification of Nucleic Acids: Molecular Cloning, Cold Spring Harbor Laboratory, New York, NY, USA, 13th edition, 1986.

[30] N. O. el Tai, O. F. Osman, M. el Fari, W. Presber, and G. Schonian, "Genetic heterogeneity of ribosomal internal transcribed spacer in clinical samples of Leishmania donovani spotted on filter paper as revealed by single-strand conformation polymorphisms and sequencing," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 94, no. 5, pp. 575-579, 2000.

[31] G. Wortmann, L. Hochberg, H.-H. Houng et al., "Rapid identification of Leishmania complexes by a real-time PCR assay," American Journal of Tropical Medicine and Hygiene, vol. 73, no. 6, pp. 999-1004, 2005.

[32] A. H. Sharief, E.-T. A. G. Khalil, D. C. Barker, S. A. Omer, H. S. Abdalla, and M. E. Ibrahim, "Simple and direct characterization of Leishmania donovani isolates based on cytochrome oxidase II gene sequences," The Open Tropical Medicine Journal, vol. 4, no. 1, pp. 1-5, 2011.

[33] N. O. el Tai, M. el Fari, I. Mauricio et al., "Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing," Experimental Parasitology, vol. 97, no. 1, pp. 35-44, 2001.

[34] K. Tamura, D. Peterson, N. Peterson, G. Stecher, M. Nei, and 5. Kumar, "MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods," Molecular Biology and Evolution, vol. 28, no. 10, pp. 2731-2739, 2011.

[35] A. M. el-Hassan and E. E. Zijlstra, "Leishmaniasis in Sudan--1. Cutaneous Leishmaniasis," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 95, supplement 1, pp. S1-S17, 2001.

[36] A. A. Belli, M. A. Miles, and J. M. Kelly, "A putative Leishmania panamensis/Leishmania braziliensis hybrid is a causative agent of human cutaneous Leishmaniasis in Nicaragua," Parasitology, vol. 109, no. 4, pp. 435-442, 1994.

[37] S. Shirian, A. Oryan, G. R. Hatam, and Y. Daneshbod, "Mixed mucosal Leishmaniasis infection caused by Leishmania tropica and Leishmania major" Journal of Clinical Microbiology, vol. 50, no. 11, pp. 3805-3808, 2012.

[38] L. J. al-Diwany, N. A. al-Awkati, M. Atia, and M. B. Rassam, "Concomitant natural infection with L. donovani and L. major: a case report from Iraq," Sozial-und Praventivmedizin, vol. 40, no. 4, pp. 234-238, 1995.

[39] Y. B. Mebrahtu, P. G. Lawyer, L. D. Hendricks et al., "Concurrent infection with Leishmania donovani and Leishmania major in a Kenyan patient: clinical description and parasite characterization," American Journal of Tropical Medicine and Hygiene, vol. 45, no. 3, pp. 290-296, 1991.

[40] C. Ravel, S. Cortes, F. Pratlong, F. Morio, J.-P. Dedet, and L. Campino, "First report of genetic hybrids between two very divergent Leishmania species: Leishmania infantum and Leishmania major" International Journal for Parasitology, vol. 36, no. 13, pp. 1383-1388, 2006.

[41] E. Martinez, S. Mollinedo, M. Torrez, M. Munoz, and A.L. Banuls, "Co-infection by Leishmania amazonensis and L. infantum/L. chagasi in a case of diffuse cutaneous Leishmaniasis in Bolivia," Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 96, no. 5, pp. 529-532, 2002.

[42] R. S. Pacheco, G. Grimaldi Junior, and C. M. Morel, "Inhibition of growth of Leishmania mexicana mexicana by Leishmania mexicana amazonensis during "in vitro" co-cultivation," Memorias do Instituto Oswaldo Cruz, vol. 82, no. 4, pp. 537-542, 1987

[43] N. M. Khalid, M. A. Aboud, F. M. Alrabba, D. E. Elnaiem, and F. Tripet, "Evidence for genetic differentiation at the microgeographic scale in Phlebotomus papatasi populations from Sudan," Parasites & Vectors, vol. 5, article 249, 2012.

[44] A. Oryan, S. Shirian, M. R. Tabandeh, G. R. Hatam, G. Randau, and Y. Daneshbod, "Genetic diversity of Leishmania major strains isolated from different clinical forms of cutaneous Leishmaniasis in southern Iran based on minicircle kDNA," Infection, Genetics and Evolution, vol. 19, pp. 226-231, 2013.

[45] J. Myskova, M. Svobodova, S. M. Beverley, and P. Volf, "A lipophosphoglycan-independent development of Leishmania in permissive sand flies," Microbes and Infection, vol. 9, no. 3, pp. 317-324, 2007.

[46] P. F P. Pimenta, E. M. B. Saraiva, E. Rowton et al., "Evidence that the vectorial competence of phlebotomine sand flies for different species of Leishmania is controlled by structural polymorphisms in the surface lipophosphoglycan," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 19, pp. 9155-9159, 1994.

[47] P. Volf, I. Benkova, J. Myskova, J. Sadlova, L. Campino, and C. Ravel, "Increased transmission potential of Leishmania major/Leishmania infantum hybrids," International Journal for Parasitology, vol. 37, no. 6, pp. 589-593, 2007

[48] M. B. Jamjoom, R. W. Ashford, P. A. Bates et al., "Leishmania donovani is the only cause of visceral Leishmaniasis in east Africa; previous descriptions of L. infantum and "L. archibaldi" from this region are a consequence of convergent evolution in the isoenzyme data," Parasitology, vol. 129, no. 4, pp. 399-409, 2004.

[49] G. Schonian, I. Mauricio, and E. Cupolillo, "Is it time to revise the nomenclature of Leishmania?" Trends in Parasitology, vol. 26, no. 10, pp. 466-469, 2010.

[50] G. van der Auwera, J. Fraga, A. M. Montalvo, and J.-C. Dujardin, "Leishmania taxonomy up for promotion?" Trends in Parasitology, vol. 27, no. 2, pp. 49-50, 2011.

A. M. Babiker, (1,2) S. Ravagnan, (1) A. Fusaro, (1) M. M. Hassan, (3) S. M. Bakheit, (4) M. M. Mukhtar, (4) G. Cattoli, (1) and G. Capelli (1)

(1) Istituto Zooprofilattico Sperimentale delle Venezie, Viale dell'Universita, 10-35020 Legnaro (PD), Italy (2) Department of Public Health and Comparative Pathology, University of Padua, Viale dell'Universita, 16-35030 Legnaro, Italy (3) Tropical Medicine Research Institute, National Centre for Research, P.O. Box 1304, Khartoum, Sudan (4) Institute of Endemic Diseases, University of Khartoum, Medical Campus, Qasr Avenue, P.O. Box 45235, 11111 Khartoum, Sudan

Correspondence should be addressed to G. Capelli; gcapelli@izsvenezie.it

Received 28 October 2013; Accepted 29 January 2014; Published 12 March 2014

Academic Editor: Lukasz Kedzierski

TABLE 1: Provenance, numbers, and types of
samples collected included in the study.

Geographic origin      Sample     Number
                        type    of samples

                       HBM *        21
Central Gedarif city    HB *        21
                       HLN *        18
Tabaraka Allah H         HB         7
                        HLN         1
South Gedarif city      HBM         5
                         HB         20
                        DNA         7
Khartoum-IEND           DNA         1
                        DNA         1
                        DNA         6

Geographic origin      Leishmaniasis     Clinical
                         diagnosis     manifestation

                        Symptomatic         VL
Central Gedarif city    Symptomatic         VL
                        Symptomatic         VL
Tabaraka Allah H        Serological         VL
                        Serological         VL
South Gedarif city      Symptomatic         VL
                        Symptomatic         VL
                          Culture           VL
Khartoum-IEND             Culture          PKDL
                          Culture           ML
                          Culture           CL

HBM: human bone marrow; HB: human blood; HLN:
human lymph node; IEND: Institute of Endemic Diseases.

* Samples from the same patients.
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Babiker, A.M.; Ravagnan, S.; Fusaro, A.; Hassan, M.M.; Bakheit, S.M.; Mukhtar, M.M.; Cattoli, G.; Ca
Publication:Journal of Tropical Medicine
Article Type:Report
Date:Jan 1, 2014
Words:5152
Previous Article:Clinical, laboratory, and management profile in patients of liver abscess from northern India.
Next Article:Clinical, molecular, and epidemiological analysis of dengue cases during a major outbreak in the Midwest region of Minas Gerais, Brazil.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters